Navigation Links
Genedata Screener Adopted for all Plate-based Screening by Major Pharmas
Date:1/14/2013

Orlando, Fla. (PRWEB) January 14, 2013

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that more than half of the world’s top 25 pharmaceutical companies have adopted Genedata Screener as their plate-based screening analysis platform. Also used by biotechnology companies, contract research organizations, and academic research institutions, Genedata Screener captures, analyzes, and manages all types of screening data on one platform. The system, which reduces data processing times by upwards to 80%, integrates with any plate-based instrument to support High, Medium and Low Throughput Screening, High Content Screening (HCS), Ion Channel Screening, Label-free (including thermal shift), and other assay technologies. Genedata Screener will be demonstrated at the 2nd Annual SLAS Conference at the Gaylord Palms Convention Center (Booth #511) with a featured tutorial scheduled for January 15.

One Platform for All Plate-based Screening
The cost savings, productivity gains, and time efficiencies of a single-platform screening analysis system with built-in business logic for standardized and automated workflows are driving the accelerated adoption of Genedata Screener. Addressing the complete screening workflow, Genedata Screener scales from the smallest datasets with single read-outs per well to 1,000s of plates in 1536-well format with full kinetics resolution. Its intuitive data analysis environment enables very fast experiment set-up, data import and processing with set-up times reduced by more than 50% compared to other systems. Genedata Screener uniquely supports the complete range of:

  • Classic Plate-based Screening Instruments: absorbance; fluorescence/Luminescence; fluorescence Polarization, FRET
  • High Content Screening: Numeric well and cell results stored in files or databases; Images from local or central image storage; Off-the shelf support for Molecular Devices MDC Store™ Data Management, openBIS for HCS, Perkin Elmer Columbus™ Image Data Management, and Thermo Scientific Cellomics® Store
  • Time Series results as produced in: FLIPR-/FDSS-based Screening; Ion Channel Screening; Label-free Screening; Thermal Shift Screening

Industry Adoption – Co-Development Drives Innovation
The system’s data analysis capabilities are further advanced through co-development projects with leading pharmaceutical companies. Currently, the Genedata team is working with customers to have Genedata Screener support native processing for calculation of compound combination effects – such as synergy or antagonistic effects. Exploring compound combination effects is a rapidly expanding field in pharmaceutical and biotechnology research. Genedata Screener provides a standardized platform on which researchers can systematically, reliably and efficiently visualize and explore the scientific principles of compound combinations is critical to furthering innovation in drug and treatment discovery.

“Over the past two years, we have seen Genedata Screener’s adoption more than double, making it the de-facto screening analysis standard at leading pharmaceutical companies,” said Dr. Othmar Pfannes, CEO of Genedata. “The increased use of Genedata Screener is also due in part to our commitment to industry collaborations that drive innovative research. For example, our collaborations will develop the industry’s first commercial platform to fully support quantification of drug combination effect as part of a complete interactive and multi-dimensional screening workflow.”

Editorial Note: SLAS Tutorial – “One Platform for All Plate-based Screening” – January 15, 2013; 2:00pm – 2:45pm; Room Destin 1-2. Demonstration will show how raw data and results are managed on one platform to drive continual comparability, efficient data analysis, and improved results.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10312425.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Screener to Present at 10th Annual Ion Channel Retreat
2. Genedata Expressionist® Established as Data Analysis Platform for Oncological Research
3. Genedata Screener for HCS Advances Phenotypic Screening
4. Research Volunteer Registry from Verified Clinical Trials Adopted by ICON
5. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
6. SpermCheck® Fertility, the Only FDA Approved At-Home Screening Test for Men to Determine Normal or Low Sperm Count, Now Available to Couples Planning or Struggling to Conceive
7. Luminex Corporation Receives CE Mark for Revolutionary Newborn Screening Platform
8. Trovagene and Strand Life Sciences Plan Collaboration to Validate and Offer Urine-Based HPV Screening Test in India and South Asia
9. BioRealm to Develop Universal Genetic Screening Tool for Tobacco Addiction and Treatment
10. Dallas-Fort Worth Fertility Associates Celebrates First Birth in North Texas from Advanced Trophectoderm Biopsy Screening Technology
11. IntelliCyt Introduces New System for Multiplexed Screening of Suspension Assays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Denmark , March 22, 2017  Ascendis ... utilizes its innovative TransCon technology to address significant ... financial results for the full year ended December ... significant year for our company as we broadened ... a leading, integrated rare disease company with an ...
(Date:3/22/2017)... 22, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... www.oramed.com ), a clinical-stage pharmaceutical company ... systems, announced today that Dr. Miriam Kidron ... presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing ... Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com ... ... cancer conditions are being pressured as of late due to ... cancer pain management has a dramatic impact on patient,s quality ... and development activities for identifying new forms of opioid formulations ...
(Date:3/22/2017)... 22, 2017   VWR (NASDAQ: ... product and service solutions to laboratory and ... acquired EPL Archives, Inc., an international biorepository ... entire regulated product research, development and commercialization ... and ancillary services. EPL Archives is widely ...
Breaking Biology Technology:
(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud with ... Reading ... Used combined in one project, multi-biometric solutions provide a crucial ... Used combined in ... ...
(Date:3/7/2017)...   HireVue , the leading provider of video ... best talent, faster, today announced the additions of ... Diana Kucer as Chief Marketing Officer (CMO). ... poised to drive continued growth in the company,s new ... record bookings in 2017. "Companies worldwide turn ...
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
Breaking Biology News(10 mins):